211 related articles for article (PubMed ID: 8717396)
1. Design of immunogens as components of a new generation of molecular vaccines.
Loktev VB; Ilyichev AA; Eroshkin AM; Karpenko LI; Pokrovsky AG; Pereboev AV; Svyatchenko VA; Ignat'ev GM; Smolina MI; Melamed NV; Lebedeva CD; Sandakhchiev LS
J Biotechnol; 1996 Jan; 44(1-3):129-37. PubMed ID: 8717396
[TBL] [Abstract][Full Text] [Related]
2. [Preparation of a specific immunogen based on bacteriophage M13].
Minenkova OO; Il'ichev AA; Kishchenko GP; Il'icheva TN; Khripin IuL; Oreshkova SF; Petrenko VA
Mol Biol (Mosk); 1993; 27(3):561-8. PubMed ID: 7686250
[TBL] [Abstract][Full Text] [Related]
3. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
4. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes.
Schödel F; Peterson D; Hughes J; Wirtz R; Milich D
J Biotechnol; 1996 Jan; 44(1-3):91-6. PubMed ID: 8717391
[TBL] [Abstract][Full Text] [Related]
5. [Design of four-helix protein--a possible vaccine against human immunodeficiency virus (HIV-1)].
Eroshkin AM; Zhilkin PA; Shamin VV
Mol Biol (Mosk); 1993; 27(3):538-51. PubMed ID: 7686249
[TBL] [Abstract][Full Text] [Related]
6. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits.
Isaguliants MG; Kadoshnikov YP; Kalinina TI; Smirnov VD; Wahren B
Biochemistry (Mosc); 1998 May; 63(5):551-8. PubMed ID: 9632891
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
8. Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.
Xu J; Ren L; Huang X; Qiu C; Liu Y; Liu Y; Shao Y
AIDS; 2006 Nov; 20(18):2293-303. PubMed ID: 17117015
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
10. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
11. [Experimental molecular design of recombinant vaccines].
Lebedev LR; Goncharova EP; Sizov AA; Bulychev LE; Odegov AM; Ryzhikov AB
Mol Biol (Mosk); 2003; 37(3):544-9. PubMed ID: 12815963
[TBL] [Abstract][Full Text] [Related]
12. [Molecular construction of experimental combined vaccines].
Lebedev LR; Sizov AA; Karpenko LI; Poryvaeva VA; Odegov AM
Mol Gen Mikrobiol Virusol; 2002; (1):17-21. PubMed ID: 11904919
[TBL] [Abstract][Full Text] [Related]
13. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
Zhang Y; Song S; Liu C; Wang Y; Xian X; He Y; Wang J; Liu F; Sun S
Cell Immunol; 2007 May; 247(1):18-27. PubMed ID: 17707782
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
[TBL] [Abstract][Full Text] [Related]
15. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
[TBL] [Abstract][Full Text] [Related]
16. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
17. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein.
Clarke BE; Newton SE; Carroll AR; Francis MJ; Appleyard G; Syred AD; Highfield PE; Rowlands DJ; Brown F
Nature; 1987 Nov 26-Dec 2; 330(6146):381-4. PubMed ID: 2446137
[TBL] [Abstract][Full Text] [Related]
18. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
Wild J; Bojak A; Deml L; Wagner R
Vaccine; 2004 Apr; 22(13-14):1732-43. PubMed ID: 15068857
[TBL] [Abstract][Full Text] [Related]
19. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.
Liu Z; Chen YH
J Immunol Methods; 2004 Feb; 285(1):93-7. PubMed ID: 14871538
[TBL] [Abstract][Full Text] [Related]
20. Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine.
Takeda S; Shiosaki K; Kaneda Y; Nakasatomi T; Yoshizaki H; Someya K; Konno Y; Eda Y; Kino Y; Yamamoto N; Honda M
Clin Immunol; 2004 Jul; 112(1):92-105. PubMed ID: 15207786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]